01

COMPANY PROFILE

公司概況

南(nán)京博天科(kē)智生(shēng)物技術有限公司作(zuò)爲國内體外診斷試劑生(shēng)産企業,前身(shēn)由南(nán)京醫科(kē)大(dà)學、江蘇省人(rén)民(mín)醫院及江蘇省科(kē)教興衛工(gōng)程高技術平台學科(kē)梯隊組建,是集研發、生(shēng)産和銷售于一體的高科(kē)技生(shēng)物技術公司,着重于體外診斷産品的自(zì)主研發;産品主要涉及心血管疾病和惡性腫瘤領域等,獲得(de)多項國家級科(kē)技獎,國家發明及實用新型專利授權多項。

As a domestic manufacturer of in vitro diagnostic reagents, Nanjing Botian Kezhi Biotechnology co., ltd. was formerly established by Nanjing Medical University, Jiangsu Provincial People's Hospital and Jiangsu Province Science and Education Rehabilitation Engineering Hi-tech Platform discipline echelon.It is a high-tech biotechnology company integrating research and development, production and sales,focuses on the independent research and development of in vitro diagnostic products.The products are mainly related to cardiovascular diseases and malignant tumors, and have won a number of national science and technology awards, and many national invention and utility model patents.

02

COMPANY DEVELOPMENT

發展曆史

2006年(nián):公司成立;

2008年(nián):獲得(de)醫療器械生(shēng)産許可(kě)證;

2009-2012年(nián):cTnI、H-FABP等産品相(xiàng)繼上市;

2013-2016年(nián):開展無創體外診斷試劑的研發;

2017年(nián):獲得(de)天使基金;

2018年(nián):無創體外診斷産品臨床試驗及注冊;

2019年(nián):公司重組,引進戰略投資人(rén);

2021年(nián):獲得(de)國家高新技術企業稱号

The company was established in 2006; 

obtained a medical device production license in 2008;

cTnI, H-FABP and other products were successively marketed from 2009 to 2012; 

R & D of non-invasive in vitro diagnostic reagents was carried out from 2013 to 2016; 

angel fund was obtained in 2017; 

Clinical trials and registration of diagnostic products in 2018;

company restructuring and introduction of strategic investors in 2019.

Won the title of national high-tech enterprise in 2021

03

COMPANY CULTURE

企業文化

我們的宗旨:科(kē)學創新、厚積薄發、嚴密質控、服務至上
我們的理(lǐ)念:無創、快(kuài)速、精準
我們的使命:專業、呵護生(shēng)命

Our aim: scientific innovation, accumulation of wealth, strict quality control, service first
Our philosophy: non-invasive, fast and accurate
Our mission: professional, care for life